Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders
Clearmind Medicine (Nasdaq: CMND) announced the publication of a U.S. patent application on October 20, 2025 for a combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines (e.g., PEA) targeting binge behavior disorders.
The application, filed through Clearmind’s collaboration with SciSparc, covers treatment of multiple binge behaviors including excessive alcohol consumption, binge eating, smoking, compulsive shopping, and problematic sexual conduct. Clearmind said this combination leverages MEAI’s neuroplastic effects with PEA’s synergistic pharmacology. The company noted it has filed 13 patents related to the collaboration and cited preclinical data supporting MEAI’s efficacy in mitigating addictive behaviors while preserving normal reward pathways.
Clearmind Medicine (Nasdaq: CMND) ha annunciato la pubblicazione di una domanda di brevetto statunitense il 20 ottobre 2025 per una terapia combinata di 5-metossi-2-aminoindano (MEAI) e N-acilethanolamines (per es. PEA) mirata ai disturbi da comportamento da binge.
L'applicazione, presentata tramite la collaborazione di Clearmind con SciSparc, copre il trattamento di molteplici comportamenti da binge tra cui consumo eccessivo di alcol, binge eating, fumo, shopping compulsivo e comportamenti sessuali problematici. Clearmind ha dichiarato che questa combinazione sfrutta gli effetti di neuroplasticità del MEAI insieme alla farmacologia sinergica della PEA. L'azienda ha inoltre specificato di aver depositato 13 brevetti legati alla collaborazione e ha citato dati preclinici a supporto dell'efficacia del MEAI nel mitigare i comportamenti di dipendenza mantenendo integri i normali percorsi di reward.
Clearmind Medicine (Nasdaq: CMND) anunció la publicación de una solicitud de patente de EE. UU. el 20 de octubre de 2025 para una terapia de combinación de 5-metoxi-2-aminoindano (MEAI) y N-aciletanolaminas (p. ej., PEA) dirigida a trastornos de conductas de atracones.
La solicitud, presentada a través de la colaboración de Clearmind con SciSparc, cubre el tratamiento de múltiples conductas de atracón, incluyendo consumo excesivo de alcohol, atracones de comida, fumar, compras compulsivas y conductas sexuales problemáticas. Clearmind dijo que esta combinación aprovecha los efectos de neuroplasticidad del MEAI con la farmacología sinérgica de la PEA. La empresa señaló que ha presentado 13 patentes relacionadas con la colaboración y citó datos preclínicos que respaldan la eficacia del MEAI para mitigar conductas adictivas mientras mantiene intactas las vías de recompensa normales.
클리어마인드 메디슨(Clearmind Medicine, 나스닥: CMND)는 2025년 10월 20일 미국 특허 출원의 발표를 발표했습니다. 이는 5-메톡시-2-아미노인단( MEAI)와 N-아실에탄올아민(예: PEA)을 결합한 치료법으로, 폭음 행동 장애를 타깃으로 합니다.
출원은 Clearmind와 SciSparc의 협력을 통해 이루어졌으며, 과다 음주, 폭음, 흡연, 강박적 쇼핑, 문제적 성행동을 포함한 여러 폭주 행동의 치료를 다룹니다. Clearmind는 이 조합이 MEAI의 신경가소성 효과와 PEA의 시너지 약리 작용을 활용한다고 말했습니다. 또한 이 회사는 협력과 관련된 13건의 특허를 출원했다고 밝혔으며, MEAI가 중독 행동을 완화하는 동시에 정상 보상 경로를 유지한다는 것을 뒷받침하는 전임상 데이터를 인용했습니다.
Clearmind Medicine (Nasdaq: CMND) a annoncé la publication d'une demande de brevet américaine le 20 octobre 2025 pour une thérapie combinée de 5-méthoxy-2-aminoindane (MEAI) et d'acétylénolamines (par ex. PEA) ciblant les troubles des comportements de frénésie.
La demande, déposée grâce à la collaboration de Clearmind avec SciSparc, couvre le traitement de multiples comportements de frénésie, notamment une consommation excessive d'alcool, des frénésies alimentaires, le tabagisme, le shopping compulsif et des conduites sexuelles problématiques. Clearmind a déclaré que cette combinaison exploite les effets de neuroplasticité du MEAI avec la pharmacologie synergique de la PEA. L'entreprise a noté avoir déposé 13 brevets liés à la collaboration et a cité des données précliniques soutenant l'efficacité du MEAI pour atténuer les comportements addictifs tout en préservant les voies de récompense normales.
Clearmind Medicine (Nasdaq: CMND) gab die Veröffentlichung eines US-Patentantrags am 20. Oktober 2025 bekannt für eine Kombinationstherapie aus 5-Methoxy-2-Aminoindan (MEAI) und N-Acylethanolaminen (z. B. PEA), die auf binge-Verhaltensstörungen abzielt.
Der Antrag, der durch Clearminds Zusammenarbeit mit SciSparc eingereicht wurde, deckt die Behandlung mehrerer Binge-Verhalten ab, einschließlich übermäßigem Alkoholkonsum, Binge-Eating, Rauchen, zwanghaftem Shopping und problematischem Sexualverhalten. Clearmind sagte, diese Kombination nutze MEAI's neuroplastische Effekte mit der synergischen Pharmakologie der PEA. Das Unternehmen stellte fest, dass es 13 Patente in Zusammenhang mit der Zusammenarbeit angemeldet hat und zitierte präklinische Daten, die die Wirksamkeit von MEAI bei der Milderung suchterzeugter Verhaltensweisen unterstützen, während normale Belohnungspfade erhalten bleiben.
Clearmind Medicine (ناسداك: CMND) أعلنت عن نشر طلب براءة أمريكي في 20 أكتوبر 2025 لعلاج مركب من 5-ميثوكسي-2-أمينوإندان (MEAI) وN-أسيليثانولامين (مثلاً PEA) يستهدف اضطرابات سلوك النَهَم.
وقد قدم الطلب من خلال تعاون Clearmind مع SciSparc، ويغطي علاج سلوكيات النَهْم المتعددة بما في ذلك استهلاك الكحول المفرط، النَهْم الغذائي، التدخين، الشراء القهري، والسلوك الجنسي الإشكالي. ذكرت Clearmind أن هذه المجموعة تستفيد من تأثيرات المرونة العصبية لـ MEAI مع الفارماكولوجيا التعاونية لـ PEA. كما أشارت الشركة إلى أنها قد قدمت 13 براءة اختراع مرتبطة بالتعاون واستشهدت ببيانات ما قبل السريرية تدعم فاعلية MEAI في التخفيف من السلوكيات الإدمانية مع الحفاظ على مسارات المكافأة الطبيعية.
Clearmind Medicine (纳斯达克：CMND)宣布于2025年10月20日公布的美国专利申请，涉及5-甲氧基-2-氨基茚烷（MEAI）与N-乙酰乙醇胺（如PEA）组合疗法，针对暴饮暴食等暴食行为障碍。
该申请通过Clearmind与SciSparc的合作提交，涵盖多种暴食行为的治疗，包括过量饮酒、暴食、吸烟、强迫性购物和存在问题的性行为。Clearmind表示，该组合利用MEAI的神经可塑性效应以及PEA的协同药理学。公司还指出已就此次合作申请了13项专利，并引用了前临床数据，支持MEAI在缓解成瘾行为的同时保持正常奖赏通路的效力。
- U.S. patent application published on Oct 20, 2025
- 13 patents filed related to MEAI and N-Acylethanolamines collaboration
- Preclinical data cited supporting MEAI efficacy against addictive behaviors
- Clinical-stage program relies on preclinical evidence; no human efficacy data reported
- No commercial or financial terms for the SciSparc collaboration disclosed
Insights
Patent publication expands IP scope but is an early, non‑exclusive catalytic milestone; clinical proof remains required.
In simple terms, the published U.S. patent application documents intellectual property around a combination therapy using MEAI and N‑Acylethanolamines, including PEA, aimed at multiple binge behaviors. The filing stems from the collaboration with SciSparc Ltd. and adds to an existing set of 13 related patent filings, which can help carve out freedom to operate and negotiating leverage for licensing or partnerships.
Key dependencies and risks include the application stage of this disclosure and the absence of human clinical outcomes in the release. Patent publication alone does not grant enforceable rights and offers limited commercial signal until claims issue and clinical data validate safety and efficacy. Watch for claim allowance, scope in issued claims, and any disclosed clinical milestones or trial initiations within the next 12–36 months to assess whether this IP converts into tangible development value.
Vancouver, Canada, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a U.S. patent application by the United States Patent and Trademark Office (USPTO) for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing binge behavior disorders.
The patent application stems from Clearmind’s ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC). This therapy targets multiple binge behaviors, including excessive alcohol consumption binge eating, smoking, compulsive shopping, and problematic sexual conduct. The combination leverages MEAI’s neuroplastic properties to reduce impulsivity and reward-seeking behavior, which, together with PEA, has shown a synergistic pharmacological effect and therefore potentially offering a breakthrough in treating substance use disorders and addictions by presenting a more effective and safer treatment than those available today.
This publication builds on Clearmind’s intellectual property portfolio. The Company has filed 13 patents related to its collaboration with SciSparc, focusing on MEAI and N-Acylethanolamines combinations for conditions such as alcohol use disorder, cocaine addiction, obesity and weight loss, and depression. Preclinical data supports MEAI's efficacy in mitigating addictive behaviors while preserving normal natural reward pathways.
“The publication of this U.S. patent application represents yet another advancement in our mission to pioneer safe and effective, next-generation treatments for binge behaviors,” said Dr. Adi Zuloff-Shani, CEO of Clearmind. “By combining MEAI’s unique neuroplastic profile with PEA’s synergistic benefits, we’re aiming to address a significant unmet needs in addiction medicine. We believe that this strengthens our position as a leader in psychedelic therapeutics and paves the way for additional clinical development.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how the combination of MEAI and PEA potentially offers a breakthrough in treating substance use disorders and addictions by presenting a more effective and safer treatment than those available today, the Company’s mission to pioneer safe and effective, next-generation treatments for binge behaviors, its aim to address significant unmet needs in addiction medicine and additional clinical development. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What did Clearmind (CMND) announce on October 20, 2025?
What disorders does the CMND patent application target?
How many patents has Clearmind filed related to the SciSparc collaboration (CMND)?
Does the CMND announcement include clinical trial results or human efficacy data?
What is the near-term significance of the U.S. patent publication for CMND shareholders?
